0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Rheumatology

Daniel J. McCarty, MD
JAMA. 1986;256(15):2108-2109. doi:10.1001/jama.1986.03380150118038.
Text Size: A A A
Published online

Lupus anticoagulants, autoantibodies to phospholipids, long thought to represent clinically irrelevant inhibitors of in vitro coagulation tests, are now strongly linked to in vivo thrombotic events, to thrombocytopenia, and to recurrent abortions. Patients with these problems may not have signs, symptoms, or serological evidence of classic systemic lupus erythematosus. Such patients can present with retinal arterial or venous occlusion to ophthalmologists, with stroke to neurologists, with thrombocytopenia to hematologists, with fetal wastage to obstetricians, or with peripheral venous thrombosis or arterial occlusive disease to general physicians. Lupus anticoagulants have also been correlated with glomerular thrombosis, infarction, and subsequent glomerular sclerosis, providing a pathogenetic mechanism for renal damage in addition to that mediated by immune-complex deposition.1 The activated partial thromboplastin time is prolonged in the presence of plasma containing lupus anticoagulants, and such prolongation is not corrected by the addition of an equal quantity of normal plasma. The prolongation of

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();